Department of Gastroenterology, Cangzhou Central Hospital, Cangzhou, 061001, China.
Department of Pathophysiology, Hebei medical university, Shijiazhuang, 050000, China.
Cancer Med. 2018 Mar;7(3):716-725. doi: 10.1002/cam4.1364. Epub 2018 Feb 23.
The human CGB5 gene encodes chorionic gonadotropin (hCG)β 5, which is aberrantly expressed in trophoblastic neoplasm and in some non-trophoblastic neoplasms. Fucntional studies observed that it involved tumor initiation, growth, and metastatic outgrowth. In this study, using data from the International Cancer Genome Consortium (ICGC) and the Cancer Genome Atlas (TCGA)-stomach adenocarcinoma (STAD), we assessed the independent prognostic value of CGB5 expression in patients with primary gastric cancer (GC). Results showed that CGB5 expression was nearly not expressed in normal GC tissues. In comparison, its expression was detected in 214 of the 415 primary GC cases (51.6%) in TCGA-STAD and was associated with poor response to primary therapy and a higher risk of recurrence and death. In early stages, CGB5 expression was not a prognostic factor in terms of OS (HR: 1.448; 95% CI: 0.811-2.588, P = 0.211) or RFS (HR: 1.659; 95% CI: 0.778-3.540, P = 0.190). However, its expression was independently associated with unfavorable OS (HR: 1.719; 95% CI: 1.115-2.651, P = 0.014) and RFS (HR: 3.602; 95% CI: 1.708-7.598, P = 0.001) in advanced stages. Using deep sequencing data from TCGA-STAD, we found that CGB5 expression was not related to its genetic amplification or DNA methylation in GC. Based on these findings, we infer that CGB5 expression is common in GC patients and its expression might independently predict poor OS and RFS in advanced stages, but not in early stages of GC.
人类 CGB5 基因编码人绒毛膜促性腺激素（hCG）β 5，它在滋养层肿瘤和一些非滋养层肿瘤中异常表达。功能研究观察到它参与肿瘤的起始、生长和转移生长。在这项研究中，我们利用国际癌症基因组联盟（ICGC）和癌症基因组图谱（TCGA）-胃腺癌（STAD）的数据，评估了 CGB5 表达在原发性胃癌（GC）患者中的独立预后价值。结果表明，CGB5 在正常 GC 组织中几乎不表达。相比之下，在 TCGA-STAD 的 415 例原发性 GC 病例中，有 214 例检测到 CGB5 的表达，并且与对原发性治疗的不良反应、复发和死亡风险增加相关。在早期，CGB5 的表达并不是 OS（HR：1.448；95%CI：0.811-2.588，P=0.211）或 RFS（HR：1.659；95%CI：0.778-3.540，P=0.190）的预后因素。然而，它的表达与不利的 OS（HR：1.719；95%CI：1.115-2.651，P=0.014）和 RFS（HR：3.602；95%CI：1.708-7.598，P=0.001）在晚期独立相关。利用 TCGA-STAD 的深度测序数据，我们发现 CGB5 的表达与 GC 中的基因扩增或 DNA 甲基化无关。基于这些发现，我们推断 CGB5 在 GC 患者中表达普遍，其表达可能在晚期独立预测不良 OS 和 RFS，但在 GC 的早期阶段则不然。
